General characteristics of cancer randomised controlled trials including elderly patients
| Variable | Category | Total (n=72) |
| International (if more than one country) | No | 48 (66.7) |
| Yes | 24 (33.3) | |
| Industry supported (fully or in part) | No | 35 (48.6) |
| Yes | 37 (51.4) | |
| Disease stage | Only metastatic/advanced | 35 (48.6) |
| Only non-metastatic/local | 27 (37.5) | |
| Both | 8 (11.1) | |
| Unclear | 2 (2.8) | |
| Overall study sample size | ≤200 | 33 (45.8) |
| >200 | 39 (54.2) | |
| Secondary paper on PRO | No | 51 (70.8) |
| Yes | 21 (29.2) | |
| Year of publication | 2004–2010 | 37 (51.4) |
| 2011–2019 | 35 (48.6) | |
| Type of treatment used* | Radiotherapy | 11 (15.3) |
| Surgery | 8 (11.1) | |
| Chemotherapy | 26 (36.1) | |
| Targeted therapy | 9 (12.5) | |
| Hormonal therapy | 26 (36.1) | |
| Other | 14 (19.4) | |
| PRO endpoint | Primary | 20 (27.8) |
| Secondary | 52 (72.2) |
*More than one option could be chosen.
PRO, patient-reported outcome.